Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections
Updated vaccines based on Omicron subvariants have started to being rolled out. Analysis of antibody response in individuals with two or three vaccine doses suggests that BA.2 breakthrough infection barely increases cross-neutralization capacity against BA.4/5 or BA.2.75.
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-34400-8 |